Treatment of axial spondyloarthritis: an update

Abhijeet Danve, Atul Deodhar

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life. The four broad categories of approved treatment options are physical therapy and exercise (which have been known to be beneficial for millennia), NSAIDs (since the 1950s), TNF inhibitors (first FDA approval in 2003) and IL-17 inhibitors (first FDA approval in 2016). In addition, there have been a host of new developments in the axSpA field, including new treatment guidelines, the FDA approval of three biologic DMARDs to treat non-radiographic axSpA, the FDA and EMA approval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or stopping TNF inhibitors in patients in remission, trials of treat-to-target strategy in axSpA, and several new molecules in phase III studies. This Review explores the developments in the management of axSpA.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalNature Reviews Rheumatology
Issue number4
StatePublished - Apr 2022

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Treatment of axial spondyloarthritis: an update'. Together they form a unique fingerprint.

Cite this